ZytoService, a leading compounder of pharmaceuticals for patient-individualised infusions, has reached an agreement with GHD GesundHeits GmbH to acquire Profusio, the second largest compounder of cytostatics in Germany. Financial terms of the transaction were not disclosed.
Founded in 2002, ZytoService is one of the largest industrially organised §13 AMG (“Arzneimittelgesetz”) certified compounders for patient-individualised infusions applied mainly in oncology treatment in Germany. The company is based in Hamburg, where it runs a state-of-the-art compounding facility.
Profusio, a subsidiary of GHD, is the second largest cytostatics compounder in Germany with state-of-the-art manufacturing facilities in Leipzig, Haan and Munich.
“Profusio’s facilities are very well-invested, and they share our high standards of quality, safety, and professional expertise. Together, we will work towards our vision to create an integrated healthcare provider in the German oncology market,” said Enno Scheel, Co-Founder of ZytoService.
“The acquisition of Profusio will strengthen ZytoService’s market position and national footprint, giving us even better opportunities to address the growing demands of the German healthcare market,” continued Thomas Boner, Co-Founder of ZytoService.
ZytoService is owned by the IK VIII Fund, which is advised by IK Investment Partners. Completion of the transaction is subject to customary legal and regulatory approvals.
For further questions:
Thomas Boner, Co-Founder and Co-CEO
Phone: +49 40 600 094 013
Enno Scheel, Co-Founder and Co-CEO
Phone: +49 40 600 094 01
ZytoService was founded in Hamburg in 2002. ZytoService now employs more than 470 highly-qualified personnel who have undergone pharmaceutical training. All staff are specially trained in GMP-compliant production. With more than 40 licensed pharmacists, ZytoService has outstanding expertise in all areas of oncological pharmacy. For more information, visit www.zytoservice.de